Patient-derived peritoneal malignant ascites provides a clinically relevant model for assessment of emerging cancer therapeutics, enabling mechanistic insights into PD-L1 BiTE efficacy in a heterogeneous TME with associated immunosuppression. Here, CD274 is linked to cancer.